Oncology | pharmaphorum

News

Astellas GLOWing as Claudin drug aces gastric cancer trial

Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.

News

Could Daiichi Sankyo have another ADC winner in cancer?

New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.

News

Merck suffers a setback in its TIGIT programme

Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.

News

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

Exscientia builds cancer pipeline with two BMS drugs

LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.

News

Merck suffers a setback in its TIGIT programme

Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.

News

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

Exscientia builds cancer pipeline with two BMS drugs

LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.

News

Astellas GLOWing as Claudin drug aces gastric cancer trial

Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.

News

Could Daiichi Sankyo have another ADC winner in cancer?

New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.

Views & Analysis

R&D

Allogeneic therapies: The future of cancer treatment?

Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.

Oncology

World Thrombosis Day at 10, talking blood clots and cancer

A new 'Move Against Thrombosis' campaign and discussion of cancer-related blood clotting.

Deep Dive

Views & Analysis

ASCO highlights: the next generation of cancer therapy

For the last two years, the American Society of Clinical Oncology (ASCO) conference has been a reminder that even when COVID dominates headlines, amazing advances are still being made in ca

Oncology

Immunotherapy: building the fourth pillar of cancer treatmen...

Cancer treatment has been traditionally characterised by surgery, chemotherapy, and radiation.

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Oncology

Sponsored

Unlocking health data to improve oncology outcomes

The NHS’ globally unique health data ecosystem has the potential to improve health outcomes.

Podcasts

Oncology

Cancer control in a time of crisis - the pharmaphorum podcas...

During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with

Oncology

Understanding the tumour micro-environment – the pharmaphoru...

As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissu

Oncology

AI-derived cancer vaccines: the pharmaphorum podcast

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science off

Video

Oncology

JP Morgan 2023 – Adi Hoess

pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about

Oncology

Health Innovators – Dr. Jack Hoppin and Dr. John Babich

A few weeks ago, pharmaphorum Editor-in-Chief Jonah Comstock popped in on Ratio Therapeutics co-founders Dr. Jack Hoppin and Dr. John Babich at their WeWork coworking

Views & Analysis

Helsinn’s Riccardo Braglia on the patient perspective in can...

Swiss cancer care company Helsinn has become unique in the industry by remaining a family business over three generations.

White Papers

Sponsored

How pharma can help the post-COVID recovery of European canc...

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians i

Oncology

Sponsored

Preparing for the next decade of innovation in immuno-oncolo...

Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.

Debates & Insight